194 related articles for article (PubMed ID: 21095264)
1. Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial.
Melloni C; Rao SV; Povsic TJ; Melton L; Kim RJ; Kilaru R; Patel MR; Talan M; Ferrucci L; Longo DL; Lakatta EG; Najjar SS; Harrington RA
Am Heart J; 2010 Nov; 160(5):795-803.e2. PubMed ID: 21095264
[TBL] [Abstract][Full Text] [Related]
2. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial.
Najjar SS; Rao SV; Melloni C; Raman SV; Povsic TJ; Melton L; Barsness GW; Prather K; Heitner JF; Kilaru R; Gruberg L; Hasselblad V; Greenbaum AB; Patel M; Kim RJ; Talan M; Ferrucci L; Longo DL; Lakatta EG; Harrington RA;
JAMA; 2011 May; 305(18):1863-72. PubMed ID: 21558517
[TBL] [Abstract][Full Text] [Related]
3. Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial infarction: results of the erythropoietin in myocardial infarction trial.
Prunier F; Bière L; Gilard M; Boschat J; Mouquet F; Bauchart JJ; Charbonnier B; Genée O; Guérin P; Warin-Fresse K; Durand E; Lafont A; Christiaens L; Abi-Khalil W; Delépine S; Benard T; Furber A
Am Heart J; 2012 Feb; 163(2):200-7.e1. PubMed ID: 22305837
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled trial to evaluate the safety and effectiveness of intracoronary application of a novel bioabsorbable cardiac matrix for the prevention of ventricular remodeling after large ST-segment elevation myocardial infarction: Rationale and design of the PRESERVATION I trial.
Rao SV; Zeymer U; Douglas PS; Al-Khalidi H; Liu J; Gibson CM; Harrison RW; Joseph DS; Heyrman R; Krucoff MW
Am Heart J; 2015 Nov; 170(5):929-37. PubMed ID: 26542501
[TBL] [Abstract][Full Text] [Related]
5. Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial.
Ludman AJ; Yellon DM; Hasleton J; Ariti C; Babu GG; Boston-Griffiths E; Venugopal V; Walker M; Holdright D; Swanton H; Crake T; Brull D; Moon JC; Puranik R; Muthurangu V; Taylor A; Hausenloy DJ
Heart; 2011 Oct; 97(19):1560-5. PubMed ID: 21900585
[TBL] [Abstract][Full Text] [Related]
6. Impact of epoetin alfa on left ventricular structure, function, and pressure volume relations as assessed by cardiac magnetic resonance: the heart failure preserved ejection fraction (HFPEF) anemia trial.
Green P; Babu BA; Teruya S; Helmke S; Prince M; Maurer MS
Congest Heart Fail; 2013; 19(4):172-9. PubMed ID: 23517485
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: rationale and design of the evaluation of MCC-135 for left ventricular salvage in acute MI (EVOLVE) study.
Jang IK; Pettigrew V; Picard MH; Kowey PR; Demmel V; Zile MR; Tatsuno J; Wackers FJ; Hibberd M
J Thromb Thrombolysis; 2005 Dec; 20(3):147-53. PubMed ID: 16261287
[TBL] [Abstract][Full Text] [Related]
8. Randomized placebo controlled trial evaluating the safety and efficacy of single low-dose intracoronary insulin-like growth factor following percutaneous coronary intervention in acute myocardial infarction (RESUS-AMI).
Caplice NM; DeVoe MC; Choi J; Dahly D; Murphy T; Spitzer E; Van Geuns R; Maher MM; Tuite D; Kerins DM; Ali MT; Kalyar I; Fahy EF; Khider W; Kelly P; Kearney PP; Curtin RJ; O'Shea C; Vaughan CJ; Eustace JA; McFadden EP
Am Heart J; 2018 Jun; 200():110-117. PubMed ID: 29898838
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporine A in Reperfused Myocardial Infarction: The Multicenter, Controlled, Open-Label CYCLE Trial.
Ottani F; Latini R; Staszewsky L; La Vecchia L; Locuratolo N; Sicuro M; Masson S; Barlera S; Milani V; Lombardi M; Costalunga A; Mollichelli N; Santarelli A; De Cesare N; Sganzerla P; Boi A; Maggioni AP; Limbruno U;
J Am Coll Cardiol; 2016 Feb; 67(4):365-374. PubMed ID: 26821623
[TBL] [Abstract][Full Text] [Related]
10. Intracoronary administration of bone marrow-derived progenitor cells improves left ventricular function in patients at risk for adverse remodeling after acute ST-segment elevation myocardial infarction: results of the Reinfusion of Enriched Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction study (REPAIR-AMI) cardiac magnetic resonance imaging substudy.
Dill T; Schächinger V; Rolf A; Möllmann S; Thiele H; Tillmanns H; Assmus B; Dimmeler S; Zeiher AM; Hamm C
Am Heart J; 2009 Mar; 157(3):541-7. PubMed ID: 19249426
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE).
Jang IK; Weissman NJ; Picard MH; Zile MR; Pettigrew V; Shen S; Tatsuno J; Hibberd MG; Tzivoni D; Wackers FJ;
Am Heart J; 2008 Jan; 155(1):113.e1-8. PubMed ID: 18082500
[TBL] [Abstract][Full Text] [Related]
12. Stem-cell therapy in ST-segment elevation myocardial infarction with reduced ejection fraction: A multicenter, double-blind randomized trial.
Nicolau JC; Furtado RHM; Silva SA; Rochitte CE; Rassi A; Moraes JBMC; Quintella E; Costantini CR; Korman APM; Mattos MA; Castello HJ; Caixeta A; Dohmann HFR; de Carvalho ACC;
Clin Cardiol; 2018 Mar; 41(3):392-399. PubMed ID: 29569254
[TBL] [Abstract][Full Text] [Related]
13. Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial.
Zohlnhöfer D; Ott I; Mehilli J; Schömig K; Michalk F; Ibrahim T; Meisetschläger G; von Wedel J; Bollwein H; Seyfarth M; Dirschinger J; Schmitt C; Schwaiger M; Kastrati A; Schömig A;
JAMA; 2006 Mar; 295(9):1003-10. PubMed ID: 16507801
[TBL] [Abstract][Full Text] [Related]
14. Bioabsorbable Intracoronary Matrix for Prevention of Ventricular Remodeling After Myocardial Infarction.
Rao SV; Zeymer U; Douglas PS; Al-Khalidi H; White JA; Liu J; Levy H; Guetta V; Gibson CM; Tanguay JF; Vermeersch P; Roncalli J; Kasprzak JD; Henry TD; Frey N; Kracoff O; Traverse JH; Chew DP; Lopez-Sendon J; Heyrman R; Krucoff MW
J Am Coll Cardiol; 2016 Aug; 68(7):715-23. PubMed ID: 27515331
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of agents to reduce infarct size: it can be quite REVEALing.
Bhatt DL
JAMA; 2011 May; 305(18):1908-9. PubMed ID: 21558525
[No Abstract] [Full Text] [Related]
16. Effect of Paroxetine-Mediated G-Protein Receptor Kinase 2 Inhibition vs Placebo in Patients With Anterior Myocardial Infarction: A Randomized Clinical Trial.
Pilgrim T; Vollenbroich R; Deckarm S; Gräni C; Dobner S; Stark AW; Erne SA; Babongo Bosombo F; Fischer K; Stortecky S; Reusser N; Fürholz M; Siontis GCM; Heg D; Hunziker L; Windecker S; Lanz J
JAMA Cardiol; 2021 Oct; 6(10):1171-1176. PubMed ID: 34259826
[TBL] [Abstract][Full Text] [Related]
17. Intracoronary versus intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: 6-month effects on infarct size and left ventricular function. The randomised Leipzig Immediate PercutaneouS Coronary Intervention Abciximab i.v. versus i.c. in ST-Elevation Myocardial Infarction Trial (LIPSIAbciximab-STEMI).
Eitel I; Friedenberger J; Fuernau G; Dumjahn A; Desch S; Schuler G; Thiele H
Clin Res Cardiol; 2011 May; 100(5):425-32. PubMed ID: 21125288
[TBL] [Abstract][Full Text] [Related]
18. A single-center prospective randomized controlled trial evaluating the safety and efficacy of IntraCoronary Erythropoietin delivery BEfore Reperfusion: gauging infarct size in patients with acute ST-segment elevation myocardial infarction. Study design and rationale of the 'ICEBERG Trial'.
Suh JW; Yoon YE; Oh IY; Yoon CH; Cho YS; Youn TJ; Chae IH; Choi DJ
Contemp Clin Trials; 2013 May; 35(1):145-50. PubMed ID: 23506972
[TBL] [Abstract][Full Text] [Related]
19. Positive effect of intravenous iron-oxide administration on left ventricular remodelling in patients with acute ST-elevation myocardial infarction - a cardiovascular magnetic resonance (CMR) study.
Florian A; Ludwig A; Rösch S; Yildiz H; Klumpp S; Sechtem U; Yilmaz A
Int J Cardiol; 2014 May; 173(2):184-9. PubMed ID: 24613367
[TBL] [Abstract][Full Text] [Related]
20. Update on phase II studies of erythropoietin in acute myocardial infarction. Rationale and design of Exogenous erythroPoietin in Acute Myocardial Infarction: New Outlook aNd Dose Association Study (EPAMINONDAS).
Andreotti F; Agati L; Conti E; Santucci E; Rio T; Tarantino F; Natale L; Berardi D; Mattatelli A; Musumeci B; Bonomo L; Volpe M; Crea F; Autore C
J Thromb Thrombolysis; 2009 Nov; 28(4):489-95. PubMed ID: 19533304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
